RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

USA - English

• APAC - English

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes

YANTAI, China, July 9, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, announced a clinical research and supply agreement with Innovent Biologics ("Innovent")  (HKEX: 01801) . This collaboration will focus on conducting clinical trials exploring combination therapies of the novel antibody-drug conjugates (ADCs), RC88 (targeting MSLN) and RC108 (targeting c-MET), along with the PD-1 inhibitor sintilimab injection (TYVYT®).

According to the agreement, Innovent will supply clinical drug supplies of sintilimab during the clinical trial collaboration, while RemeGen will conduct Phase I/IIa clinical studies in China. The trials will assess the safety, tolerability, and preliminary efficacy of RC88 or RC108 combined with sintilimab in Chinese cancer patients.

RemeGen's independently developed ADC, RC88, targets mesothelin (MSLN) and was approved for Phase I clinical trials in China in November 2018. Preliminary results show that RC88 monotherapy exhibits anti-tumor activity against MSLN-expressing solid tumors and demonstrates manageable safety. The combined use of RC88 with immune checkpoint inhibitors (ICIs) such as PD-1/PD-L1 can induce immunogenic cell death (ICD), releasing a series of signaling molecules to further activate T cells, and enhancing the tumor immune response.

Similarly, RC108, another ADC independently developed by RemeGen targeting c-MET, was approved for Phase I clinical trials in November 2020. The ongoing trials indicate the potential of RC108 monotherapy against c-MET-expressing solid tumors, with manageable safety. Preclinical research suggests that RC108 induces tumor-specific adaptive immunity and increases T cell infiltration in the tumor microenvironment, while PD-1 monoclonal antibodies activate T cells, enhancing the anti-tumor immune response. Therefore, it is expected that the combination therapy of RC108 and TYVYT can enhance both the presentation of tumor antigens by dendritic cells and the killing of tumor cells by T cells, resulting in enhanced tumor suppression.

TYVYT, a PD-1 inhibitor developed collaboratively by Innovent and Eli Lilly and Company (NYSE: LLY), has been approved for seven indications, six of which have been included in China's National Reimbursement Drug List (NRDL). It is the only PD-1 inhibitor to include first-line treatment for the five major high-incidence solid tumors (non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer), and also the first and only immunotherapy drug in the field of gastric cancer to be included in the NRDL.

"The alliance with Innovent is a critical step forward in the research and commercialization strategy of combination therapies with RC88 and RC108," said Su Na, Senior Vice President of RemeGen. "By combining these therapies with sintilimab, we offer innovative treatment plans that target two pathways. These mechanisms are complementary, potentially helping to overcome or delay treatment resistance and provide an effective solution to unmet clinical needs."

"We are thrilled to join forces with RemeGen to unlock the potential of combining sintilimab injection with novel ADCs," added Dr. Zhou Hui, Senior Vice President of Innovent. "Preclinical studies have suggested that combining ADCs with an anti-PD-1 monoclonal antibody may improve patient outcomes and overcome drug resistance. As immunotherapy advanced into the next era of development, we hope to strengthen the leading position of sintilimab as a backbone immunotherapy as well as investigate the new opportunities of combination therapies, and provide better treatment options for more cancer patients."

About RemeGen Co. Ltd.

Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: www.remegen.cn

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines in the fields of oncology, metabolism, autoimmunity, ophthalmology and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to RemeGen, are intended to identify certain of such forward-looking statements. RemeGen does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of RemeGen with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond RemeGen's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, RemeGen's competitive environment and political, economic, legal and social conditions.

RemeGen, the Directors and the employees of RemeGen assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.

SOURCE RemeGen Co., Ltd